Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.280
-0.060 (-4.48%)
At close: Oct 29, 2025, 4:00 PM EDT
1.300
+0.020 (1.55%)
After-hours: Oct 29, 2025, 7:53 PM EDT
Revelation Biosciences Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Revelation Biosciences in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Revelation Biosciences.
Recommendation Trends
| Rating | Dec '22 | Jan '23 | Feb '23 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $7,200 → $21,600 | Strong Buy | Maintains | $7,200 → $21,600 | +1,687,400.00% | Feb 14, 2023 |
| Roth Capital | Roth Capital | Strong Buy Initiates $604,800 | Strong Buy | Initiates | $604,800 | +47,249,900.00% | Feb 17, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-8.89
from -263.05
EPS Next Year
-1.99
from -8.89
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.58 | -2.05 | |||
| Avg | -8.89 | -1.99 | |||
| Low | -11.88 | -1.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.